Jack Chan

Dr. Jack Chan


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Science Advances
Verified
Journal Article
Open access
SLSer Yue Loo
Ser Yue Loo
LTLi Ping Toh
Li Ping Toh
WXWilliam Haowei Xie
William Haowei Xie
EPElina Pathak
Elina Pathak
WTWilson Tan
Wilson Tan
WTWai Leong Tam
Wai Leong Tam
Fatty acid oxidation is a metabolic gateway that regulates cellular plasticity and supports metastasis in breast cancer.

1 January 2019 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
JCJack Chan
Jack Chan
TTTira J. Y. Tan
Tira J. Y. Tan
RDRebecca A. Dent
Rebecca A. Dent
Multiomic analyses have shed light upon the molecular heterogeneity and complexity of triple-negative breast cancers (TNBCs). With increasing recognition that TNBC is not a single disease entity but encompasses different disease subtypes, a one-size-fits-all treatment paradigm has become obsolete. In this context, the inhibition of phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and androgen receptor (AR) signaling pathways have emerged as potential therapeutic strategies against selected tumors. In this paper, we reviewed the preclinical rationale, predictive biomarkers, efficacy, and safety data from early phase trials, and the future directions for these two biomarker-directed treatment approaches in TNBC.

8 September 2023 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
JMJun Ma
Jun Ma
JCJack Chan
Jack Chan
CTChing Han Toh
Ching Han Toh
YYYoon-Sim Yap
Yoon-Sim Yap
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the standard first-line treatment for most patients with hormone receptor (HR) positive, human epidermal growth factor receptor (HER2) negative advanced breast cancer. However, resistance to ET and CDK4/6i inevitably ensues. The optimal post-progression treatment regimens and their sequencing continue to evolve in the rapidly changing treatment landscape. In this review, we summarize the mechanisms of resistance to ET and CDK4/6i, which can be broadly classified as alterations affecting cell cycle mediators and activation of alternative signaling pathways. Recent clinical trials have been directed at the targets and pathways implicated, including estrogen and androgen receptors, PI3K/AKT/mTOR and MAPK pathways, tyrosine kinase receptors such as FGFR and HER2, homologous recombination repair pathway, other components of the cell cycle and cell death. We describe the findings from these clinical trials using small molecule inhibitors, antibody–drug conjugates and immunotherapy, providing insights into how these novel strategies may circumvent treatment resistance, and discuss how some have not translated into clinical benefit. The challenges posed by tumor heterogeneity, adaptive rewiring of signaling pathways and dose-limiting toxicities underscore the need to elucidate the latest tumor biology in each patient, and develop treatments with improved therapeutic index in the era of precision medicine.

1 September 2020 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
JCJack Chan
Jack Chan
YSYirong Sim
Yirong Sim
SOSamuel GW OW
Samuel GW OW
JLJoline Si Jing Lim
Joline Si Jing Lim
GKGrace Kusumawidjaja
Grace Kusumawidjaja
TTTira Jing Ying Tan
Tira Jing Ying Tan
The ensuing COVID-19 pandemic poses unprecedented and daunting challenges to the routine delivery of oncological and supportive care to patients with breast cancer. Considerations include the infective risk of patients who are inherently immunosuppressed from their malignancy and therapies, long-term oncological outcomes from the treatment decisions undertaken during this extraordinary period, and diverted healthcare resources to support a coordinated whole-of-society outbreak response. In this review, we chronicle the repercussions of the COVID-19 outbreak on breast cancer management in Singapore and describe our approach to triaging and prioritising care of breast tumours. We further propose adaptations to established clinical processes and practices across the different specialties involved in breast oncology, with references to the relevant evidence base or expert consensus guidelines. These recommendations have been developed within the unique context of Singapore’s public healthcare sector. They can serve as a resource to guide breast cancer management for future contingencies in this city-state, while certain elements therein may be extrapolatable to other medical systems during this global public health emergency.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
DADaniel Jia Ming Ang
Daniel Jia Ming Ang
JCJack Chan
Jack Chan
Ang DJ, et al. J Gynecol Oncol. 2024 Jan;35:e65. https://doi.org/10.3802/jgo.2024.35.e65

31 October 2018 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
CTChia Jie Tan
Chia Jie Tan
SLSheree Wan Ting Lim
Sheree Wan Ting Lim
YTYi Long Toh
Yi Long Toh
TNTerence Ng
Terence Ng
AYAngie Yeo
Angie Yeo
ACAlexandre Chan
Alexandre Chan
Cancer-related cognitive impairment (CRCI) adversely affects cancer patients. We had previously demonstrated that the BDNF Val66Met genetic polymorphism is associated with lower odds of subjective CRCI in the multitasking and verbal ability domains among breast cancer patients receiving chemotherapy. To further assess our previous findings, we evaluated the association of BDNF Val66Met polymorphism with subjective and objective CRCI in a temporally separate cohort of patients and pooled findings from both the original (n = 145) and current (n = 193) cohorts in a meta-analysis. Subjective CRCI was assessed using FACT-Cog. Objective CRCI was evaluated using computerized neuropsychological tests. Genotyping was carried out using Sanger sequencing. The association of BDNF Val66Met genotypes and CRCI was examined with logistic regression. A fixed-effect meta-analysis was conducted using the inverse variance method. In the meta-analysis (n = 338), significantly lower odds of CRCI were associated with Met allele carriers based on the global FACT-Cog score (OR = 0.52, 95% CI 0.29–0.94). Furthermore, Met allele carriers were at lower odds of developing impairment in the domains of memory (OR = 0.34, 95% CI: 0.17–0.70), multitasking (OR = 0.33, 95% CI: 0.18–0.59), and verbal ability (OR = 0.46, 95% CI: 0.24–0.88). Consistent with the previous study, lower odds of subjective CRCI among patients with the BDNF Met allele was observed after adjusting for potential confounders in the multitasking (OR = 0.30, 95% CI: 0.14–0.67) domain. In conclusion, carriers of the BDNF Met allele were protected against global subjective CRCI, particularly in the domains of memory, multitasking, and verbal ability. Our findings further contribute to the understanding of CRCI pathophysiology.